Trabedersen
drugOn this page
Also known as A-12009 FREE ACID
Summary
Trabedersen (CHEMBL2108345) is a phase-3 clinical-stage oligonucleotide; indicated across 7 conditions including glioblastoma and anaplastic astrocytoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Oligonucleotide
- Indications: 7 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108345 |
| Name | Trabedersen |
| Type | Oligonucleotide |
| Max phase | 3 |
Also known as: A-12009 FREE ACID, Trabedersen, TRABEDERSEN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| glioblastoma | 3 | MONDO:0018177 | EFO:0000519 |
| anaplastic astrocytoma | 3 | MONDO:0016684 | EFO:0002499 |
| malignant pleural mesothelioma | 2 | MONDO:0005112 | EFO:0000770 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| pancreatic ductal adenocarcinoma | 2 | MONDO:0005184 | MONDO:0005184 |
| lung neoplasm | 2 | MONDO:0021117 | MONDO:0008903 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00761280 | PHASE3 | TERMINATED | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma |
| NCT06579196 | PHASE1/PHASE2 | RECRUITING | Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 |
| NCT05935774 | PHASE2 | WITHDRAWN | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: glioblastoma, anaplastic astrocytoma